KROS Keros Therapeutics, Inc.
Price Chart
Executive Summary
Keros Therapeutics reported Q1 2026 EPS of -$1.21, a 31.5% miss vs consensus of -$0.92, and revenue of $0.367M, 78.4% below the $1.7M estimate. The net loss of $23.7M compares to net income of $148.5M in Q1 2025, driven by the absence of Takeda license revenue and reduced R&D spend. Cash runway extends into H1 2028, but the revenue collapse and EPS miss signal a pre-commercial biotech with no near-term catalysts beyond Takeda's Phase 3 plans.
Actionable Insight
The revenue collapse and EPS miss confirm Keros is a pre-revenue clinical-stage biotech with no approved products. The Takeda partnership provides a potential catalyst but no near-term revenue. Monitor for elritercept Phase 3 data and any pipeline updates; the cash runway provides a floor but the stock is likely to trade on binary trial outcomes.
Key Facts
- Q1 2026 EPS of -$1.21 missed consensus of -$0.92 by 31.5%
- Q1 2026 revenue of $0.367M missed consensus of $1.7M by 78.4%
- Net loss of $23.7M vs net income of $148.5M in Q1 2025
- Revenue collapsed 99.8% YoY due to absence of Takeda license revenue
- Cash and equivalents $281.5M, expected runway into H1 2028
- Takeda plans Phase 3 trial for elritercept in myelofibrosis anemia
- Weighted-average shares outstanding fell to 19.6M from 40.6M YoY due to treasury stock
Financial Impact
EPS miss of $0.29 (31.5%) and revenue miss of $1.33M (78.4%) on a $237M market cap
Risk Factors
- No approved products or recurring revenue stream
- Dependence on Takeda partnership for elritercept development
- Clinical trial failure risk for rinvatercept and elritercept
- Dilution risk from potential future equity offerings
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3294851 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 8, 2026
1d ago
|
Insider Cluster
| $9.99 awaiting T+5 | awaiting T+5 | — | $10.00 (+0.10%) |
|
May 14, 2026
26d ago
|
8-K
| $10.99 $11.22 | ▼ −2.09% | ▼ −2.81% | $10.00 (+9.01%) |
|
May 14, 2026
26d ago
|
Press Release
| $10.99 $11.22 | ▼ −2.09% | ▼ −2.81% | $10.00 (+9.01%) |
|
Apr 22, 2026
6w ago
|
DEFA14A
| $11.56 $11.10 | ▼ −3.98% | ▼ −5.46% | $10.00 (−13.49%) |
|
Apr 1, 2026
10w ago
|
144
| $11.69 $12.49 | ▲ +6.84% | ▲ +3.08% | $10.00 (−14.46%) |
|
Mar 9, 2026
13w ago
|
Press Release
| $11.35 $11.03 | ▼ −2.82% | ▼ −1.46% | $10.00 (−11.89%) |
|
Mar 4, 2026
13w ago
|
8-K
| $11.71 $10.99 | ▼ −6.15% | ▼ −3.91% | $10.00 (−14.60%) |
|
Mar 4, 2026
13w ago
|
8-K
| $11.71 $10.99 | ▼ −6.15% | ▼ −3.91% | $10.00 (−14.60%) |
|
Mar 4, 2026
13w ago
|
Press Release
| $11.71 $10.99 | ▼ −6.15% | ▼ −3.91% | $10.00 (−14.60%) |
|
Feb 28, 2026
14w ago
|
Institutional Cluster
| $13.91 $11.35 | ▼ −18.40% | ▼ −17.20% | $10.00 (−28.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access